Clal Biotechnology | CBI - Operating Expenses


Clal Biotechnology reported ILS5.15M in Operating Expenses for its fiscal quarter ending in December of 2022.





Operating Expenses Change Date
Arca Biopharma USD 25.09M 5.23M Mar/2025
aTyr Pharma USD 26.94M 6.63M Sep/2025
Bio Path USD 3.24M 616K Mar/2025
Brainstorm Cell Therapeutics USD 3.09M 100K Mar/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
Immunic USD 25.73M 2.91M Sep/2024
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
RedHill Biopharma USD 5.51M 1.08M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024